IV magnesium for acute menstrual cramp pain
Evaluation of Intravenous Magnesium Administration in the Treatment of Dysmenorrhea
This trial will test whether a single IV dose of magnesium sulfate relieves severe menstrual cramp pain in women 18–35 better than IV dexketoprofen.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 35 Years |
| Sex | Female |
| Sponsor | Gaziosmanpasa Research and Education Hospital Government |
| Locations | 1 site (Gaziosmanpaşa, Outside of the US) |
| Trial ID | NCT07248540 on ClinicalTrials.gov |
What this trial studies
This double-blind, randomized trial enrolls women aged 18–35 presenting to the emergency department with primary dysmenorrhea and a VAS pain score of ≥6. Participants are assigned to receive either two ampoules of IV magnesium sulfate or IV dexketoprofen, each diluted in 100 mL saline and given over 15 minutes. Pain is measured on a Visual Analog Scale before treatment and one hour after administration, with secondary outcomes including patient satisfaction, vital sign changes, and adverse effects. The trial compares the short-term analgesic effectiveness and safety profile of IV magnesium versus a standard NSAID for acute dysmenorrhea.
Who should consider this trial
Good fit: Women aged 18–35 with primary dysmenorrhea, regular menstrual cycles, a VAS pain score ≥6 at presentation, not pregnant or breastfeeding, and willing to provide informed consent at the enrolling emergency department.
Not a fit: Patients with secondary dysmenorrhea or underlying gynecologic pathology, pregnancy or breastfeeding, recent use of analgesics/muscle relaxants, renal failure, cardiac arrhythmia, or known allergy to the study drugs are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, IV magnesium could provide a rapid alternative to NSAIDs for emergency relief of severe menstrual cramps, potentially reducing NSAID exposure.
How similar studies have performed: Some small studies and observational data suggest magnesium can reduce menstrual and musculoskeletal pain, but randomized head-to-head comparisons with NSAIDs are limited, so this specific comparison is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Female patients aged 18 to 35 years Presenting to the obstetrics and gynecology emergency department with a diagnosis of primary dysmenorrhea Having regular menstrual cycles within the last 6 months Having a Visual Analog Scale (VAS) pain score of ≥6 at emergency admission Providing written informed consent for participation in the study Exclusion Criteria: Patients with secondary dysmenorrhea or underlying gynecological pathology Pregnancy or breastfeeding Use of analgesics or muscle relaxants within the last 3 days Known allergy to magnesium sulfate or dexketoprofen trometamol History of renal failure, cardiac arrhythmia, or serious systemic disease Inability to assess pain due to mental disability or communication disorder Failure to provide informed consent for participation in the study
Where this trial is running
Gaziosmanpaşa, Outside of the US
- SBÜ Gaziosmanpaşa Training and Research Hospital — Gaziosmanpaşa, Outside of the US, Turkey (Türkiye) (Recruiting)
Study contacts
- Principal investigator: havva betül bacak, md — SBÜ Gaziosmanpaşa Training and Research Hospital
- Study coordinator: ecenur çelikoğlu, md
- Email: ecenurcelikoglu14@gmail.com
- Phone: +90 538 54 92 848
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.